Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin-Reference-Cited by-同舟云学术

Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin

Published:2014-01-03 Issue:1 Volume:18 Page:66-81
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Bowles Paul¹,Brenek Steven J.¹,Caron Stéphane¹,Do Nga M.¹,Drexler Michele T.¹,Duan Shengquan¹,Dubé Pascal¹,Hansen Eric C.¹,Jones Brian P.¹,Jones Kris N.¹,Ljubicic Tomislav A.¹,Makowski Teresa W.¹,Mustakis Jason¹,Nelson Jade D.¹,Olivier Mark¹,Peng Zhihui¹,Perfect Hahdi H.¹,Place David W.¹,Ragan John A.¹,Salisbury John J.¹,Stanchina Corey L.¹,Vanderplas Brian C.¹,Webster Mark E.¹,Weekly R. Matt¹

Affiliation:

1. Chemical Research and Development, ‡Analytical Research and Development, Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/op4002802

Reference36 articles.

1. Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus

2. Pharmacodynamic Model of Sodium–Glucose Transporter 2 (SGLT2) Inhibition: Implications for Quantitative Translational Pharmacology

3. Pharmacokinetics, Metabolism, and Excretion of the Antidiabetic Agent Ertugliflozin (PF-04971729) in Healthy Male Subjects

4. Mascitti, V.; Collman, B. M.,Preparation of dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives as antidiabetic agents. Application: WO/2009/IB53626, 2010/023594, 2010.

5. Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Fries-Type Rearrangement Strategy for the Construction of Stereodefined Quaternary Pseudoanomeric Centers: An Entry into C-Naphthyl Ketosides;The Journal of Organic Chemistry;2023-09-21

2. Pharmaceutical cocrystal and their role in improving solid state properties of active pharmaceutical ingredients;Al Mustansiriyah Journal of Pharmaceutical Sciences;2023-05-22

3. Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality;Pharmaceuticals;2023-02-22

4. Opportunities and Challenges in Mechanochemical Cocrystallization toward Scaled-Up Pharmaceutical Manufacturing;Organic Process Research & Development;2023-02-13

5. Formal Glycosylation of Quinones with exo-Glycals Enabled by Iron-Mediated Oxidative Radical–Polar Crossover;The Journal of Organic Chemistry;2022-09-12